The effects of gaviscon and metoclopramide in gastroesophageal reflux in children

J Pediatr Gastroenterol Nutr. 1986 Jul-Aug;5(4):556-9. doi: 10.1097/00005176-198607000-00008.

Abstract

Oral metoclopramide (0.5 mg/kg/24 h) and a liquid alginic acid-antacid compound were administered to infants and children with gastroesophageal reflux (GER) in a double-blind randomized controlled trial. The effect of medication was measured with 24-h intraesophageal pH monitoring. Neither metoclopramide nor the alginic acid-antacid compound decreased the frequency or duration of gastroesophageal reflux.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Alginates / therapeutic use*
  • Aluminum Hydroxide / therapeutic use*
  • Antacids / therapeutic use*
  • Bicarbonates / therapeutic use*
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Double-Blind Method
  • Drug Combinations / therapeutic use
  • Gastroesophageal Reflux / drug therapy*
  • Humans
  • Infant
  • Metoclopramide / therapeutic use*
  • Random Allocation
  • Silicic Acid / therapeutic use*
  • Silicon Dioxide / therapeutic use*
  • Sodium Bicarbonate*

Substances

  • Alginates
  • Antacids
  • Bicarbonates
  • Drug Combinations
  • Silicic Acid
  • Aluminum Hydroxide
  • alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination
  • Silicon Dioxide
  • Sodium Bicarbonate
  • Metoclopramide